The company has identified inhibitors of a novel target which have potential to reverse the metabolic complications in T2D. The current treatments in T2D are not effective in all patients and there is a high medical need for novel curative anti-diabetic drugs which can replace or complement current therapies.
Impact: Reduce patient suffering/mortality and healthcare expenses
CEO: Prof. Margit Mahlapuu
GUV Contact: Lorna Fletcher